Neurava

What Neurava does

Neurava Inc. is a pre-commercial medical device company founded in 2019 and spun out of Purdue University, developing an AI-powered wearable platform for epilepsy patients at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The platform comprises two wearable devices — the A1, which detects and alerts for convulsive seizures via an innovative seizure-sensing array, and the N1, which holistically monitors cardiac, respiratory, and oxygenation signals — plus a smartphone Mobile App that streams data over Bluetooth to Neurava Cloud and delivers AI-powered alerts to caregivers and EMS, and a Physician Portal for retrospective clinical review. The company's underlying scientific premise, derived from research in Dr. Pedro Irazoqui's Purdue lab, links seizure-induced cardiorespiratory collapse to SUDEP, positioning Neurava as a first-in-class solution for the 35% of the 3.5 million Americans with epilepsy whose condition is drug-resistant and who face elevated SUDEP risk, particularly during sleep when 70% of SUDEP cases occur and 90% are unwitnessed.

Neurava is pursuing a hybrid revenue model combining hardware sales (A1 and N1 wearables) with recurring software/subscription services spanning the Mobile App, cloud infrastructure, and Physician Portal access. Pricing is not publicly disclosed as the company remains pre-FDA-clearance, but go-to-market plans target two channels: direct-to-consumer outreach to patients and caregivers, and enterprise sales to neurologists, epileptologists, and epilepsy centers. Clinical validation is underway through usability studies at six clinical centers, with FDA pre-submission meetings completed for both the A1 (March 2021) and N1 (November 2024) devices; a near-SUDEP case study has been published in 'Epileptic Disorders', and a $4 million NIH Blueprint MedTech Optimizer award funds development of a SUDEP risk stratification and forecasting algorithm over up to four years.

The company has raised approximately $10-11 million cumulatively across pre-seed, seed, Series Seed, and SEC-filed exempt offerings, alongside non-dilutive NIH and MedTech Innovator awards. Strategic investors include Life Science Angels (Series Seed lead), Elevate Ventures, Purdue Innovates, First Leaf Capital, Rivermount Ventures, and notably UCB, a global epilepsy leader providing both capital and strategic validation. The team is led by co-founders Jay Shah, PhD (Co-CEO) and Vivek Ganesh, PhD (Co-Founder, ex-Apple Health Technologies), with Lead Algorithms Engineer Trevor Meyer, PhD (Johns Hopkins), and a Board of Directors strengthened in December 2024 by Daniel Moore, former CEO of Cyberonics and Chairman of LivaNova, and Jed Kay of Elevate Ventures. Headquartered in Baltimore, MD, Neurava operates with 1-10 employees and targets a tele-epilepsy and AI-driven seizure wearable market projected to reach $3.87 billion by 2030 at a 22.3% CAGR.

Name

Neurava

Legal name

Neurava Inc.

Website

https://neurava.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurava develops an AI-powered dual-wearable platform (A1 seizure detection, N1 cardiorespiratory monitoring) plus Mobile App and Physician Portal to predict SUDEP risk and alert caregivers for people with drug-resistant epilepsy.

Ownership category

akta.pro rank

Product category

Wearable Epilepsy Monitoring Devices

NAICS

Computer Systems Design Services (541512)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Wearable medical devices
• Epilepsy monitoring
• SUDEP prevention
• Seizure detection
• Cardiorespiratory monitoring

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Wearable Device Sales: The company develops and plans to commercialize wearable medical devices (A1 and N1) for epilepsy monitoring and SUDEP risk alerting. Revenue will come from hardware sales of the wearable devices.
2. Software/Subscription Services: AI-powered algorithms and cloud platform require ongoing monitoring and alert services. Likely subscription-based model for software services, mobile app, and physician portal access.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Neurava is developing an AI-powered wearable platform for epilepsy patients at risk of SUDEP (Sudden Unexpected Death in Epilepsy). The platform comprises two wearable devices — the A1 (convulsive seizure detection) and the N1 (cardiac, respiratory, and oxygenation monitoring) — paired with a Mobile App that delivers AI-powered alerts to caregivers and EMS, and a Physician Portal providing retrospective clinical data for healthcare professionals. The platform is built on proprietary algorithms and research linking seizure-induced cardiorespiratory collapse to SUDEP.

Product overview

Neurava offers an AI-powered wearable platform comprising two wearable devices (A1 and N1), a smartphone Mobile App, and a Physician Portal. The A1 detects and alerts for convulsive seizures while the N1 monitors cardiac, respiratory, and oxygenation signals. Both wearables transmit data via Bluetooth to the Mobile App, which processes the information through AI algorithms and connects to Neurava Cloud for data storage. When a risk event is detected, instant alerts notify caregivers and EMS. The Physician Portal provides healthcare professionals with comprehensive retrospective patient data and monitoring tools.

Differentiator

Problem solved

Functional benefit

Brands

• A1: Wearable device that reliably records and alerts for convulsive seizures using innovative seizure sensing array with industry leading performance.
• N1

Products and services

• A1 Wearable Device Wearable device that reliably records and alerts for convulsive seizures using an innovative seizure sensing array with industry-leading performance. Designed for nighttime monitoring of epilepsy patients, particularly those with drug-resistant epilepsy at risk of SUDEP.
• N1 Wearable Device Wearable device that seamlessly captures cardiac, respiratory, and oxygenation signals holistically, alerting to any deviations from normal ranges. Complements the A1 by monitoring cardiorespiratory dysfunctions induced by seizures.
• Mobile App AI-powered smartphone application that constantly monitors incoming data from A1 and N1 wearables via Bluetooth. Delivers alerts with high confidence for potential events to caregivers and EMS, and allows users to capture medication history, notes, and reports.
• Physician Portal Web-based application tailored for medical professionals, delivering comprehensive insights on retrospective data and patient monitoring tools for clinical review of epilepsy patients.

Quantifiable outcome

• Industry-leading seizure detection performance with low false alert rate
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• FDAcoreOthersConducted FDA pre-submission meetings to introduce A1 (January 2020) and N1 (November 2024) devices, clarifying regulatory pathways for both products.
• Clinical Research CenterscoreStrategic or Co-development PartnerUsability studies conducted at 6 clinical centers validating A1 and N1 devices against clinical gold standard. EMU (Epilepsy Monitoring Unit) reference data collected for algorithm development.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• EpiTel: EpiTel develops the REMI wearable EEG sensor for long-term seizure monitoring in epilepsy patients. It is a direct competitor in the wearable neurological monitoring space, targeting similar ambulatory use cases.
• iRhythm Technologies: iRhythm's Zio is a wearable cardiac diagnostic with a hardware + AI services business model. While focused on cardiac arrhythmias, it is a close analog in wearable diagnostic design, AI-driven analysis, and recurring service revenue.
• Empatica: Empatica's EpiMonitor (Embrace) is an FDA-cleared wearable for seizure detection in epilepsy patients. It is the most direct head-to-head competitor to Neurava's A1 device, though Empatica focuses on seizure detection rather than SUDEP risk stratification.
• BioSerenity: BioSerenity provides wearable EEG and remote monitoring solutions for neurology, including epilepsy. It competes with Neurava in ambulatory seizure monitoring and connected neurology diagnostics.

Broad incumbents

• NeuroPace: NeuroPace's RNS System is an FDA-approved closed-loop neurostimulation device for drug-resistant epilepsy. It addresses the same patient population as Neurava and is an established neuro device incumbent with regulatory and commercialization advantages.
• Medtronic: Medtronic's Neuroscience portfolio includes implanted neurostimulators and diagnostics for epilepsy. It is a broad incumbent with deep regulatory, clinical, and commercial resources that dwarf early-stage wearable peers like Neurava.
• LivaNova: LivaNova (formerly Cyberonics) provides vagus nerve stimulation therapy for drug-resistant epilepsy. Neurava's board director Daniel Moore is a former CEO. It targets the same drug-resistant epilepsy population with an implanted (rather than wearable) solution.
• Preventice Solutions (Boston Scientific): Preventice, acquired by Boston Scientific, offers BodyGuardian-style remote cardiac monitoring wearables. While cardiac-focused, it exemplifies a connected wearable diagnostic + monitoring service model analogous to Neurava's planned commercial approach.

Emerging players

• Byteflies: Byteflies, via the SeizeIT2 consortium, develops wearable EEG solutions for seizure detection in epilepsy patients. It overlaps with Neurava's wearable neurology monitoring focus but is earlier-stage and consortium-driven.
• Ceribell: Ceribell provides AI-enabled point-of-care EEG for seizure detection in hospital and ICU settings. It overlaps with Neurava in AI-driven neurological monitoring and shares the wearable/portable neurology diagnostic category, though primarily inpatient rather than ambulatory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurava

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurava